Key practice guidelines around the world recommend bevacizumab in combination with platinum-based chemotherapy for the first-line treatment of metastatic
non-small cell lung cancer patients with predominant non-squamous histology.
In this patient group, bevacizumab-based treatment has been shown to be the treatment option with the longest progression and overall survival demonstrated to date. The aim of this review is to investigate and discuss the value of the outcomes of bevacizumab-based treatment from the perspectives of physicians, payers and patients.
Available evidence suggest that patients value bevacizumab treatment as it offers extended periods without disease progression and, hence, delays the negative consequences of metastatic non-small cell lung cancer to the patients' health status and quality of life. The treatment is considered valuable for clinical practice as it enables physicians to offer an effective, safe, and innovative therapy that addresses the principal areas of unmet need in metastatic non-small cell lung cancer treatment. Bevacizumab-based treatment has gained positive appraisal by policy makers in many countries around the world, and hence has allowed payers to give access to therapy that has benefits that expand to the wider societal context and public health.
Evidence on the economic value of bevacizumab-based treatment is associated with mixed results, due to the considerable differences in the healthcare settings. In the European and Asian settings, bevacizumab-based treatment has been shown to offer good value for money. In addition, reviewed analyses that used wider societal perspective showed that outcomes of adding bevacizumab to platinum-based therapy can be associated with savings from reduced productivity losses.
Adding bevacizumab to the chemotherapy doublet in first-line, non-squamous, metastatic non-small cell lung cancer provides value for each stakeholder
in the context of metastatic non-small cell lung cancer care.